Positron emission tomography after fetal transplantation in Huntington's disease
- 27 July 2005
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 58 (2) , 331-337
- https://doi.org/10.1002/ana.20564
Abstract
H untington's disease (HD) is a progressive disorder with no known cure. We report two‐year postoperative positron emission tomography (PET) data from 7 HD patients who underwent intrastriatal fetal transplantation. Patients showed widespread reductions in glucose uptake with no significant change over 2 years. Dopamine receptor binding was significantly reduced in HD striatum. D1 binding did not change significantly following transplantation, but there was a significant loss of D2 binding. These findings may reflect loss of graft viability and/or disease progression. There was no significant relationship between changes in PET and clinical function. In summary, there was no benefit from transplantation. Ann Neurol 2005;58:331–337Keywords
This publication has 9 references indexed in Scilit:
- Striatal neural grafting improves cortical metabolism in Huntington's disease patientsBrain, 2004
- Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET studyBrain, 2003
- Bilateral human fetal striatal transplantation in Huntington’s diseaseNeurology, 2002
- Fetal neural grafts for Huntington's disease: A prospective viewMovement Disorders, 2002
- Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathologyProceedings of the National Academy of Sciences, 2000
- Motor and cognitive improvements in patients with Huntington's disease after neural transplantationThe Lancet, 2000
- Huntington's disease progressionBrain, 1999
- Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's diseaseBrain, 1996
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993